Scholarlink

<p>The objective is to evaluate the clinical efficacy and compare perioperative outcomes comparing the Da Vinci and Hinotori robotic systems in the treatment of urological tumors. We systematically reviewed an observational controlled study comparing the two systems in urologic tumor surgery. Six studies, published between 2023 and 2024, involving 904 patients, were included. Surgical parameters and postoperative outcomes were analyzed using Review Manager 5.4, p &lt; 0.05 considered statistically significant. The Da Vinci system demonstrated significantly shorter operation time (OT) (WMD = 22.48, p &lt; 0.001) and robotic intervention time (RIT) (WMD = 23.35, p &lt; 0.001) compared to the Hinotori system. No significant differences were observed in estimated blood loss (EBL), major complications (MC), positive surgical margin rate (PSM), or biochemical recurrence (BCR) between the two groups. Sensitivity analysis confirmed the robustness of these findings, although moderate to high heterogeneity was noted in some outcomes. The Da Vinci robotic system is more efficient in terms of operation and robotic intervention time. However, both the Hinotori and Da Vinci systems provide comparable functional and oncologic outcomes. Given the novelty of the Hinotori system, further prospective studies with larger sample sizes are needed to validate these findings and assess long-term outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparison of perioperative outcomes and prognosis between Da Vinci surgical system and Hinotori system in urologic tumor surgery: evidence from controlled trials

  • 期刊论文

  • 发表日期：

    2025年2月28日

查看全文
  • Kangyu Wang,
  • Li Wang,
  • Jiangwei Man,
  • Jianwei Yang,
  • Hao Wang,
  • Yalong Zhang,
  • Li Yang

摘要

The objective is to evaluate the clinical efficacy and compare perioperative outcomes comparing the Da Vinci and Hinotori robotic systems in the treatment of urological tumors. We systematically reviewed an observational controlled study comparing the two systems in urologic tumor surgery. Six studies, published between 2023 and 2024, involving 904 patients, were included. Surgical parameters and postoperative outcomes were analyzed using Review Manager 5.4, p < 0.05 considered statistically significant. The Da Vinci system demonstrated significantly shorter operation time (OT) (WMD = 22.48, p < 0.001) and robotic intervention time (RIT) (WMD = 23.35, p < 0.001) compared to the Hinotori system. No significant differences were observed in estimated blood loss (EBL), major complications (MC), positive surgical margin rate (PSM), or biochemical recurrence (BCR) between the two groups. Sensitivity analysis confirmed the robustness of these findings, although moderate to high heterogeneity was noted in some outcomes. The Da Vinci robotic system is more efficient in terms of operation and robotic intervention time. However, both the Hinotori and Da Vinci systems provide comparable functional and oncologic outcomes. Given the novelty of the Hinotori system, further prospective studies with larger sample sizes are needed to validate these findings and assess long-term outcomes.